Kairos Pharma jumps on prostate cancer trial data

Shares of drug developer Kairos Pharma KAPA.A surge 77% to near 5-month high of $1.21

Stock set for its best day in about 6 months, if gains hold

Co says its experimental cancer therapy, ENV-105, was well tolerated in patients with advanced prostate cancer in an ongoing mid-stage study

ENV-105 was tested in combination with standard hormone therapy, apalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), a condition where tumors grow despite hormone-blocking treatments

Co expects to release interim efficacy data from the trial in Sept

More than 182 million shares traded, 154 times their 25-day moving avg

Including session moves, stock down 20% YTD